Stevenson Heather L, Prats Mariana M, Sasatomi Eizaburo
Department of Pathology, The University of Texas Medical Branch, John Sealy Annex Building - Room 2.148, 301 University Blvd., Galveston, TX, 77555-0588, USA.
Department of Pathology, The University of Texas Medical Branch, John Sealy Annex Building, 301 University Blvd., Galveston, TX, 77555-0588, USA.
BMC Cancer. 2017 Jan 7;17(1):35. doi: 10.1186/s12885-016-2998-2.
Preoperative neoadjuvant therapy for colorectal liver metastases (CRLM) is increasing in use and can lead to chemotherapy-induced damage to sinusoidal integrity, namely sinusoidal obstruction syndrome (SOS). SOS has been associated with an increased need for intraoperative blood transfusions, increased length of hospitalization post-surgery, decreased tumor response, and a shorter overall survival after resection due to liver insufficiency. It is critical for clinicians and pathologists to be aware of this type of liver injury, and for pathologists to include the status of the background, non-neoplastic liver parenchyma in their pathology reports. In this study, expression of CD34 by sinusoidal endothelial cells (SECs), increased expression of smooth muscle actin (SMA) by hepatic stellate cells (HSCs), and aberrant expression of glutamine synthetase (GS) by noncentrizonal hepatocytes were semiquantitatively evaluated in liver resection or biopsy specimens from patients with CRLM to determine their diagnostic value for assessing chemotherapy-induced sinusoidal injury (CSI).
The expression of each marker was compared among 22 patients with CRLM with histologically evident SOS (SOS+) and 8 patients with CRLM who had not undergone chemotherapy. Each case was given a histologic grade using the sinusoidal obstruction syndrome index score (SOS-I) to assess the likelihood of SOS. Cases were also given an immunohistochemical grade using the total CSI score calculated as the sum of CD34, SMA, and GS scores.
Abnormal staining patterns for CD34 and SMA were significantly more frequent and extensive in SOS+ cases than in the controls (81.8% vs. 25%, P < 0.01; 72.7% vs. 25%, P = 0.03). Aberrant GS expression in midzonal and periportal hepatocytes was only observed in SOS+ cases (31.8% vs. 0%), but this difference did not reach statistical significance. The CSI score was significantly higher in the SOS+ cases when compared to controls (P < 0.01), and was associated with a higher SOS histologic grade (P = 0.02).
The CSI score, calculated using an immunohistochemical panel consisting of CD34, SMA, and GS, may serve as an objective marker of chemotherapy-induced sinusoidal injury and could help diagnose this peculiar form of liver injury.
结直肠癌肝转移(CRLM)的术前新辅助治疗应用日益广泛,可导致化疗引起肝血窦完整性损伤,即肝血窦阻塞综合征(SOS)。SOS与术中输血需求增加、术后住院时间延长、肿瘤反应降低以及肝切除术后因肝功能不全导致的总生存期缩短有关。临床医生和病理医生了解这种肝损伤类型至关重要,病理医生应在病理报告中纳入背景非肿瘤性肝实质的状态。在本研究中,对CRLM患者肝切除或活检标本中肝血窦内皮细胞(SECs)的CD34表达、肝星状细胞(HSCs)的平滑肌肌动蛋白(SMA)表达增加以及非中央区肝细胞谷氨酰胺合成酶(GS)的异常表达进行半定量评估,以确定其对评估化疗诱导的肝血窦损伤(CSI)的诊断价值。
比较22例组织学上有明显SOS的CRLM患者(SOS+)和8例未接受化疗的CRLM患者中各标志物的表达。使用肝血窦阻塞综合征指数评分(SOS-I)对每个病例进行组织学分级,以评估SOS的可能性。病例还使用免疫组织化学分级,即总CSI评分,计算方法为CD34、SMA和GS评分之和。
SOS+病例中CD34和SMA的异常染色模式比对照组更频繁、更广泛(81.8%对25%,P<0.01;72.7%对25%,P = 0.03)。仅在SOS+病例中观察到中区和汇管区肝细胞的GS异常表达(31.8%对0%),但这种差异未达到统计学意义。与对照组相比,SOS+病例的CSI评分显著更高(P<0.01),且与更高的SOS组织学分级相关(P = 0.02)。
使用由CD34、SMA和GS组成的免疫组织化学检测板计算的CSI评分,可作为化疗诱导的肝血窦损伤的客观标志物,有助于诊断这种特殊形式的肝损伤。